GRIN2B mutations in west syndrome and intellectual disability with focal epilepsy. by Lemke, JR et al.
ORIGINAL ARTICLE
GRIN2B Mutations in West Syndrome
and Intellectual Disability with Focal
Epilepsy
Johannes R. Lemke, MD,1,2 Rik Hendrickx, BSc,3,4 Kirsten Geider, MSc,5
Bodo Laube, PhD,5 Michael Schwake, PhD,6 Robert J. Harvey, PhD,7
Victoria M. James, PhD,7 Alex Pepler, MBiol,7,8 Isabelle Steiner, MSc,8
Konstanze H€ortnagel, MD,8 John Neidhardt, PhD,9 Susanne Ruf, MD,10
Markus Wolff, MD,10 Deborah Bartholdi, MD,11 Roberto Caraballo, MD,12
Konrad Platzer, MD,13 Arvid Suls, PhD,2,3 Peter De Jonghe, MD, PhD,2,3,4,14
Saskia Biskup, MD, PhD,8,11,15 and Sarah Weckhuysen, MD2,3,4
Objective: To identify novel epilepsy genes using a panel approach and describe the functional consequences of
mutations.
Methods: Using a panel approach, we screened 357 patients comprising a vast spectrum of epileptic disorders for
defects in genes known to contribute to epilepsy and/or intellectual disability (ID). After detection of mutations in a
novel epilepsy gene, we investigated functional effects in Xenopus laevis oocytes and screened a follow-up cohort.
Results: We revealed de novo mutations in GRIN2B encoding the NR2B subunit of the N-methyl-D-aspartate (NMDA)
receptor in 2 individuals with West syndrome and severe developmental delay as well as 1 individual with ID and focal
epilepsy. The patient with ID and focal epilepsy had a missense mutation in the extracellular glutamate-binding domain
(p.Arg540His), whereas both West syndrome patients carried missense mutations within the NR2B ion channel-forming
re-entrant loop (p.Asn615Ile, p.Val618Gly). Subsequent screening of 47 patients with unexplained infantile spasms did
not reveal additional de novo mutations, but detected a carrier of a novel inherited GRIN2B splice site variant in close
proximity (c.2011-5_2011-4delTC). Mutations p.Asn615Ile and p.Val618Gly cause a significantly reduced Mg21 block
and higher Ca21 permeability, leading to a dramatically increased Ca21 influx, whereas p.Arg540His caused less severe
disturbance of channel function, corresponding to the milder patient phenotype.
Interpretation: We identified GRIN2B gain-of-function mutations as a cause of West syndrome with severe develop-
mental delay as well as of ID with childhood onset focal epilepsy. Severely disturbed channel function corresponded to
severe clinical phenotypes, underlining the important role of facilitated NMDA receptor signaling in epileptogenesis.
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Epileptic encephalopathies (EEs) constitute a group ofdisorders in which the epileptic activity itself is con-
sidered to contribute to severe cognitive impairment or
decline above and beyond what might be expected from
the underlying pathology alone.1 West syndrome belongs
to this heterogeneous group of disorders presenting with
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distinctive clinical and electrophysiological features usu-
ally manifesting between 3 and 12 months as clusters of
infantile spasms (IS) and a characteristic electroencepha-
logram (EEG) pattern called hypsarrhythmia.2 The etiol-
ogy of West syndrome is very diverse, and a substantial
subgroup is considered to have a genetic origin. West
syndrome has been associated with mutations in ARX,
CDKL5, STXBP1, and ST3GAL3 as well as various copy
number variations (CNVs).3–7 However, in many cases
the genetic defect remains unresolved.
Mutations in GRIN2A and GRIN2B encoding the
alpha and beta-2 subunits (NR2A and NR2B) of the
glutamate-activated N-methyl-D-aspartate (NMDA)
receptor are associated with several neurodevelopmental
disorders. Mutations in GRIN2A have recently been
detected in idiopathic focal epilepsy with rolandic spikes
and related epileptic encephalopathies, that is, in Lan-
dau–Kleffner syndrome, epilepsy with continuous spike-
and-waves during slow sleep syndrome, and nonsyn-
dromic epilepsy associated with intellectual disability
(ID).8–11 By contrast, GRIN2B has not been described as
an epilepsy gene to date but has repeatedly been consid-
ered as a putative candidate gene for seizures,8,12 and
mutations were detected in patients with ID, autism
spectrum disorders (ASD), and schizophrenia.8,13–18
Materials and Methods
We used a targeted massive parallel resequencing approach to
diagnostically screen 357 individuals (Cohort A) with a broad
range of epilepsy phenotypes. The panel contained 50 known
genes comprising EE genes, plus genes for severe ID not associ-
ated with seizures, but nevertheless suspected to be involved in
epileptogenesis (eg, voltage-sensitive and ligand-gated ion-chan-
nel genes). Analysis was performed as described previously.19
Ninety-one of the 357 individuals were diagnosed with EE.
Detailed clinical information necessary for a more specific epi-
lepsy syndrome classification was not available for many of
these 91 patients. After detecting de novo mutations in
GRIN2B within Cohort A, we subsequently screened 47
patients with unexplained IS (Cohort B) by conventional meth-
ods. Three patients were diagnosed with Ohtahara syndrome
and 38 with West syndrome, and 6 patients had a nonsyn-
dromic early onset EE with IS during the course of the disease.
Sequence Analysis
We performed direct Sanger sequencing to detect point mutations/
small indels as well as multiplex amplicon quantification (MAQ)
to detect CNVs in DNA extracted from peripheral blood. All 13
exons and intron–exon boundaries of GRIN2B were analyzed by
bidirectional sequencing with the BigDye Terminator v3.1 Cycle
Sequencing kit on an ABI3730 DNA Analyzer (Applied Biosys-
tems, Foster City, CA; primers available upon request).
Additionally, the genomic region containing GRIN2B was
screened for CNVs by use of an in-house–developed technique
for MAQ (http://www.multiplicom.com/multiplex-amplicon-
quantification-maq) in Cohort B. This assay comprises a multi-
plex polymerase chain reaction (PCR) amplification of fluores-
cently labeled target and reference amplicons, followed by
fragment analysis on the ABI3730 DNA Analyzer.20 The com-
parison of normalized peak areas between the test individual
and the average of 5 control individuals results in the target
amplicon doses indicating the copy number of the target ampli-
con (using the in-house–developed Multiplex Amplicon Quan-
tification Software; http://www.multiplicom.com/maq-s). The
multiplex PCR reaction consists of 10 test amplicons located in
the genomic region of GRIN2B and 6 reference amplicons ran-
domly located on different chromosomes (primer mix is avail-
able upon request).
In Silico Prediction
Pathogenic implications of identified coding variants were
assessed by different in silico analysis programs (PolyPhen2,
http://genetics.bwh.harvard.edu/pph2/ and MutationTaster,
http://www.mutationtaster.org; Table 1). For intronic single
nucleotide polymorphisms, splice site analysis was performed
using HSF2.4 (http://umd.be/HSF/).
The mutation of the ligand-binding domain in GRIN2B
encoding human NR2B was analyzed using the x-ray crystal
structure21 of rat NR2A (Protein Data Bank # 2A5S). Rat
NR2A and human NR2B share 82% sequence identity and
88% sequence similarity in their glutamate-binding regions,
making the rat NR2A structure a useful template for the analy-
sis of mutations in GRIN2B. The interactive visualization pro-
gram University of California, San Francisco (UCSF)
Chimera22 was used for structural analysis. The “swapaa” com-
mand was used to substitute amino acids, selecting the side
chain from the Dunbrack backbone-dependent rotamer library
based on lowest number of clashes, highest number of hydrogen
bonds, and highest probability.
Molecular modeling of the transmembrane domains of
NR1/NR2B receptors was based on the crystal structure of
GluR2 (Brookhaven Protein Data Bank entry 3KG2) using
Modeller 9v6 (UCSF Sali Lab) and lsqman 9.7.9 (Uppsala
Software Factory, Uppsala, Sweden) as described.21 Models
were subjected to short-term molecular dynamics simulations
using the Charmm27 force field, which is implemented in the
Tinker 4.2 molecular modeling software (http://dasher.wus-
tl.edu/tinker/). Figures were made using PyMOL 1.2 (http://
www.pymol.org).
Functional Investigations
For Xenopus laevis oocyte experiments, NR1-1a and NR2B con-
structs and capped cRNAs were generated as described previ-
ously.8 Mutations were introduced into these constructs using
the QuikChange site-directed mutagenesis kit (Stratagene, Agi-
lent Technologies, Santa Clara, CA) and confirmed by Sanger
DNA sequencing. Individual stage V to VI oocytes were
obtained from anaesthetized frogs and isolated by collagenase
treatment. Ten nanograms of total NR1/NR2B cRNA were
injected into oocytes. Following injection, oocytes were kept at
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17C in ND96 solution (96mM NaCl, 2mM KCl, 1.8mM
CaCl2, 1mM MgCl2, 5mM HEPES, pH 7.4). Glutamate and
glycine dose–response curves of wild-type NR1/NR2B and
mutant NMDA receptors were analyzed by 2-electrode voltage-
clamp recording as described.23 Concentration–response curves
and current traces shown in the figures were drawn using Kalei-
daGraph (Synergy Software, Reading, PA). To monitor the volt-
age dependence of NR1-NR2B receptor combinations, whole-
cell current-voltage relationships of saturating glutamate- and
glycine-induced currents were recorded in 20mV intervals rang-
ing from 290mV to 130mV and normalized to the current
value obtained at 130mV above the respective reversal potential
as described previously.24 The relative divalent to monovalent
permeability was calculated by the Goldman–Hodgkin–Katz
constant field voltage equation assuming no anion permeability.
The internal concentrations of Na1 and K1 used in the calcu-
lations were 20mM and 150mM, respectively.24 Permeability
ratios were calculated for each oocyte and then averaged. Mg21
inhibition (1mM) was evaluated in the presence of 1.8mM
Ca21 at a holding potential of 270mV upon application (5
seconds) of saturating glycine (10lM) and glutamate (100lM)
concentrations.
Statistical Analyses
Values given represent means6 standard error of the mean. Sta-
tistical significance was determined at the p< 0.05, p< 0.01,
and p< 0.001 levels using Student 2-tailed, unpaired t test.
Results
Sequence Analysis and Functional Investigations
Among the 357 patients of Cohort A, we identified 2 indi-
viduals with West syndrome (Patients 1 and 2) carrying
novel heterozygous de novo mutations in GRIN2B
(2 of 91 EE cases, 2.2%) affecting key amino acids
(p.Val618Gly and p.Asn615Ile) within the NR2B ion
channel-forming re-entrant loop, as well as a patient with
ID and childhood onset focal epilepsy (Patient 3) carrying
a novel heterozygous de novo mutation (p.Arg540His)
within the NR2B glutamate-binding domain (see Table,
Fig 1).
Mutation p.Asn615Ile (Patient 2) affects 1 of 2
paired asparagines (Asn615, Asn616 in NR2B) in the re-
entrant pore-forming loop implicated in Mg21 block, and
p.Val618Gly (Patient 1) is in close vicinity. Expression of
NR1/NR2BAsn615Ile and NR1/NR2BVal618Gly heteromers
revealed a significant loss of ion-channel block by extracel-
lular Mg21 and a dramatically increased Ca21 permeabil-
ity (Fig 2), consistent with a gain of function and
consequent hyperexcitability. By contrast, p.Arg540His
(Patient 3) affects a highly conserved residue located in
the extracellular glutamate-binding region. Mutation of
p.Arg540His is predicted to abolish the hydrogen bonding
with the backbone of Cys746 and His802, and a cation–
pi interaction with His802, possibly leading to a relaxed
fold in this region (Fig 3). Curiously, rather than affecting
glutamate binding, p.Arg540His also resulted in a
decrease of Mg21 block and increase of Ca21 permeabil-
ity, implying an allosteric effect for this mutation. How-
ever, the functional impacts were less severe, in line with
the milder phenotype of the patient (see Fig 2).
Among the 47 patients of Cohort B, we detected 1
additional West syndrome patient (Patient 4) with a
novel paternally inherited heterozygous splice-site variant
deleting 2 base pairs of the splice acceptor site of exon
10, which encodes parts of the ion-channel pore domain
of GRIN2B. In silico prediction suggests a consecutive
FIGURE 1: Location of GRIN2B mutations in a schematic illustration of the conserved domains of the NR2B subunit (SP5 signal
peptide; ATD5amino-terminal domain, involved in receptor assembly; S1 and S2 form the ligand-binding domain; Pore5 re-
entrant pore-forming and transmembrane spanning domains; PDZ5PDZ domain binding motif). All reported de novo muta-
tions and their according phenotypes (ASD5autism spectrum disorders; FE5 focal epilepsy; ID5 intellectual disability;
LGS5 Lennox–Gastaut syndrome; Scz5 schizophrenia) are listed in the top row. Mutations causing phenotypes without seiz-
ures are labeled in black, mutations in epilepsy patients are in red. So far, no pathogenic variants have been observed in the
C-terminal region of NR2B. Mutations causing West syndrome cluster within re-entrant pore-forming domain, whereas the
mutation causing ID and focal epilepsy was observed in the glutamate-binding domain S1, similar to a recently described LGS
case. Nonsynonymous variants that are believed not to be associated with abnormal phenotypes (gray) and are reported more
than once (in brackets) in the Exome Variant Server (EVS) are listed in the bottom line.
Lemke et al: GRIN2B Mutations in Epilepsy
January 2014 149
alternative splice acceptor site 6 base pairs downstream of
the mutated splice site that is only marginally weaker
compared to the wild-type splice acceptor site. Use of
this alternative splice acceptor site is predicted to result
in an in-frame deletion of amino acids Phe671 and
Gln672 (p.Phe671_Gln672del) of the GRIN2B pore
complex, which would be in line with the location of the
mutations of the 2 West syndrome patients described
above. However, the latter putative splice variation was
inherited from the patient’s healthy father, and no fresh
sample or tissue was available to functionally confirm the
potentially aberrant splicing. Screening for copy number
variations by MAQ did not reveal additional deletions or
duplications affecting GRIN2B in Cohort B.
Patient Phenotypes
Patient 1 was a male born at term after an uneventful preg-
nancy. Myoclonic jerks and infantile spasms occasionally
FIGURE 2: Structural and functional consequences of missense mutations in GRIN2B. (A) Topology model of an NR1 and an
NR2B subunit. Positions of the alterations p.Arg540His, p.Asn615Ile and p.Val618Gly are indicated by asterisks in the NR2 sub-
unit consisting of an amino-terminal domain (ATD), the ligand-binding domain (LBD) including the S1 and S2 peptide segments,
3 transmembrane segments (M1, M2, and M3), a re-entrant pore loop (P), and an intracellular carboxy-terminal domain (CTD).
Residue Arg540 lies within the glutamate-binding domain, and Asn615 and Val618 in the ion channel pore. N5NH2-terminus;
C5COOH-terminus. (B) Model of the transmembrane arrangement of the N-methyl-D-aspartate (NMDA) receptor composed
of NR1 (green) and NR2B (cyan) subunits (top view). The arrow highlights the side chains of p.Asn615Ile and p.Val618Gly in
the pore-forming region. (C) Gradual loss of Mg21 inhibition of NR1-NR2B wild-type and NR1-NR2B mutant receptor currents
at 270mV. Respective sample traces of NR1-NR2B and NR1-NR2BAsn615Ile are shown above with inhibition of receptor currents
by 1mM Mg21 of NR1-NR2B (9660.9%, n54) and mutant NR1-NR2BAsn615Ile (1467.2%, p<0.0001, n53), NR1-NR2BVal618Gly
(4866.5%, p50.0003, n53), and NR1-NR2BArg540His (8163.2%, p50.005, n55) receptors. (D) Effect on Ca21 permeability
of NR1-NR2B wild-type and NR1-NR2B mutant receptor currents. Current–voltage relationships of NR1-NR2B receptors in the
absence of Mg21 in Na1-free extracellular solution reveal significant differences in the reversal potential (indicated by arrows)
of NR1-NR2B (23161.7mV, n54, black triangles) and mutant NR1-NR2BAsn615Ile (21.066.8mV,p50.004, n53, red squares),
NR1-NR2BVal618Gly (25.463.7mV, p<0.001, n53, green squares), and NR1-NR2BArg540His (29.466.5mV, p50.013, n53,
blue squares) receptor currents. (NMDG-Cl, N-methyl-D-glucamine chloride) Calculation of the relative divalent to monovalent
cation permeability PCa/PNa by the Goldman–Hodgkin–Katz voltage equation revealed a >3-fold increase in Ca21 permeability
of the mutant NMDA receptors (PCa/PNa for NR1-NR2B50.86; NR1-NR2BAsn615Ile55.22; NR2BVal618Gly53.12; and
NR2BArg540His53.23).
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occurring in clusters at the age of 4 months led to the diag-
nosis of West syndrome. At 6 months old, he held no eye
contact and presented with episodic hyperextension of axial
muscles. The result of first EEG was not available for
review. EEG at age 8 months showed multifocal bursts of
irregular spike waves as well as rhythmic bilateral general-
ized spike waves with a frequency of 4 to 5 per second
reminiscent of modified hypsarrhythmia. During sleep,
there was rare irregular high-amplitude epileptiform activity
with a hypsarrhythmialike pattern. Treatment with vigaba-
trin and pyridoxine led to a slight clinical improvement.
Replacement of vigabatrin by levetiracetam improved nei-
ther seizures (predominantly of myoclonic type) nor EEG
pattern, whereas implementation of valproate finally led to
a significant reduction of seizure frequency. At last follow-
up at age of 2 years and 1 month, the boy’s length was at
P90, weight at P25, and head circumference at P50. He
had severe axial hypotonia with episodic hyperextension
and could not sit independently. He could hold eye contact
only briefly before drifting away. At this time, the boy pre-
sented additionally with dystoniclike movements of his fin-
gers and still had no verbal communication.
FIGURE 3: Structural and functional analyses of the glutamate binding-domain mutation Arg540His. (A) Residue 540 is pre-
dicted to be located within the glutamate-binding S1 domain, and is significant in the stabilization of the tertiary structure of
the glutamate-binding domain. (B) Substitution p.Arg540His is likely to abolish hydrogen bonding (blue lines) with the back-
bone of Cys746 and His802 and a cation–pi interaction with His802, possibly leading to a relaxed fold in this region. (C) Phar-
macological characterization of the apparent agonist affinities of wild-type NR1-NR2B (black triangles) and mutant NR1-
NR2BArg540His (red squares) N-methyl-D-aspartate receptors measured after heterologous expression in Xenopus laevis oocytes
by 2-electrode voltage-clamping revealed that similar glutamate concentrations were required to elicit half-maximal responses
(EC50 values50.7260.22lM and 0.3160.02lM, respectively, p50.14, n53). (D) Arg540 is a highly conserved residue within
NR2A–D subunits.
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Patient 2 was a female born at term after an
uneventful pregnancy. At the age of 7 weeks, she pre-
sented with infantile spasms. She held no eye contact
and showed muscular hypotonia. She had episodic hyper-
extension of axial muscles. These episodes were not
recorded on video EEG, and an epileptic nature could
not be excluded. Brain magnetic resonance imaging
(MRI), magnetic resonance spectroscopy, cerebrospinal
investigation, and metabolic workup were normal. EEG
showed typical hypsarrhythmia. Treatment with vigaba-
trin, sulthiame, and topiramate failed to decrease seizures,
whereas implementation of steroid pulse therapy led to
an improvement. At last follow-up at age 5 years and 3
months, the girl is not able to sit independently. She pre-
sented with autisticlike behavior and no verbal expres-
sion, severe feeding difficulties, and mild microcephaly.
The EEG showed increased theta activity without epilep-
tic discharges. The girl still exhibits series of epileptic
spasms as well as occasional generalized tonic–clonic
seizures.
Patient 3 was a female born at 41 weeks after an
uneventful pregnancy and conception by in vitro fertil-
ization. Early development was delayed, as she sat at 11
months, walked at 19 months, and used her first words
at 18 months. At the age of 3 years, she was diagnosed
with global developmental delay. There was no evidence
for stagnation or even regression of development. Since
the age of 9 years and 9 months she had focal dyscogni-
tive seizures with postictal paresis of the right arm as well
as occasional bilateral convulsive seizures and status epi-
lepticus. Postictal EEG showed slowing over the left fron-
toparietal region, and MRI of the brain showed postictal
diffusion restriction in the same region that resolved over
time. Lumbar puncture and metabolic screening were
normal. At the last follow-up at the age of 10 years and
6 months she had a mild intellectual disability and occa-
sional seizures with postictal paresis.
Patient 4 was a male born at term after an unevent-
ful pregnancy. At the age of 2 months epileptic spasms
occurred, which soon evolved into asymmetric tonic seiz-
ures. EEG at the age of 7 months showed hypsarrhyth-
mia, and multifocal epileptic activity was seen at the age
of 14 months. MRI of the brain, metabolic workup, and
lumbar puncture were all normal. At last follow-up at
the age of 4 years, he still had daily therapy-resistant
tonic seizures and focal motor seizures. He had severe
intellectual disability with hypotonic muscle tone and
was unable to talk or walk.
Discussion
Our investigations revealed de novo GRIN2B missense
mutations in 2 of 91 patients with unexplained EE
(2.2%) and in 1 patient with ID and childhood onset
focal epilepsy. We also detected 1 novel inherited putative
splice variant in 1 of 47 patients with IS. The observa-
tion of a possibly reduced penetrance of an inherited
splice variant in Patient 4 is in agreement with previous
observations9 in families carrying mutations and putative
splice variants in GRIN2A. However, much larger data
sets are needed to prove a role of inherited GRIN2B var-
iants as risk factors for these disorders.
Interestingly, the very recent study of the Epi4K
consortium revealed 1 additional case of a de novo muta-
tion in GRIN2B in 1 of 115 individuals with epileptic
encephalopathy of Lennox–Gastaut type (see Fig 1).12
The patient shows parallels to Patient 3 of our present
study. Both mutations p.Arg540His (Patient 3) and
p.Cys461Phe (Epi4K patient) are located in the
TABLE 1. Mutations Detected in GRIN2B
Patient Phenotype Mutation Prediction
(MutationTaster/
Polyphen-2)
Origin Domain Functional
Effect
1 West
syndrome
c.1853T>G, p.Val618Gly Disease
causing/damaging
De novo Channel pore Gain of
function
2 West
syndrome
c.1844A>T, p.Asn615Ile Disease
causing/damaging
De novo Channel pore Gain of
function
3 Focal
epilepsy
& ID
c.1619G>A, p.Arg540His Disease
causing/damaging
De novo Glutamate-
binding
domain
Gain of
function
(mild)
4 West
syndrome
c.2011-5_2011-4delTC Not applicable Paternal Not applicable Potential splice
defect
ID5 intellectual disability.
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extracellular glutamate-binding region, and both patients
presented with primary developmental delay and child-
hood onset epilepsy.
NMDA receptors are tetrameric ligand-gated ion
channels permeable to Na1, K1, and Ca21, composed of
2 glycine-binding NR1 subunits and 2 glutamate-binding
NR2 subunits (NR2A, NR2B, NR2C, NR2D).25,26 Subu-
nit composition of NMDA receptors is spatially and tem-
porally regulated with a switch from predominant NR2B
expression in early development to more prominent synap-
tically localized NR2A expression at later stages,27,28 which
might explain the tendency toward earlier onset epilepsy
phenotypes in GRIN2B versus GRIN2A mutation carriers.
NMDA receptor subunits are organized into multiple
structural domains (see Fig 1) including a signal peptide,
an amino-terminal domain involved in receptor assembly,
S1 and S2 segments that form the ligand binding domain,
3 membrane-spanning domains M1–M3, and a re-entrant
pore-forming loop. Lastly, a large intracellular C-terminus
and PDZ domain-binding motif mediate interactions with
intracellular proteins such as PSD95. In the Exome Variant
Server (EVS; National Heart, Lung, and Blood Institute
Exome Sequencing Project, http://evs.gs.washington.edu/
EVS/), 38 missense and no putative essential splice variants
are listed in GRIN2B in 6503 healthy controls. The
described variants are unevenly distributed, with the vast
majority (27 of 38) of variants being positioned within the
NR2B C-terminus. Only 9 of 38 variants were detected
repeatedly, and again 7 of these are within the C-terminus.
Curiously, the only described de novo aberration within the
NR2B C-terminus was detected in an apparently healthy
control subject,29 whereas all known pathogenic GRIN2B
mutations causing neurodevelopmental disorders are found
within the N-terminal region, ligand-binding S1 and S2
segments, and the re-entrant pore-forming loop (see Fig
1).8,13–18 This suggests that pathogenic mutations affecting
key functional motifs have a greater impact on protein
function and can negatively influence neurodevelopment
and brain excitability. This is also reflected by the finding
that variants outside the C-terminus of GRIN2B occurred
significantly more frequently in alleles of EE individuals of
Cohorts A and B compared to the EVS controls
(p5 0.0027, Fisher exact test).
Interestingly, 2 of the West syndrome patients pre-
sented gain-of-function mutations (Patient 1, p.Val618Gly
and Patient 2, p.Asn615Ile) in the re-entrant pore-forming
loop. By contrast, Patient 3 with ID, childhood onset
focal epilepsy, and less severe developmental delay carried
a milder gain-of-function mutation (p.Arg540His), posi-
tioned in the extracellular glutamate-binding S1 domain.
Additionally, in support of the hypothesis that epilepsy is
caused by gain-of-function mutations in GRIN2B, truncat-
ing and thus predicted loss-of-function mutations have
only been described in patients with ID and/or ASD so
far.18 These data suggest a distinct genotype–phenotype
correlation, although more mutations and functional stud-
ies are needed to verify this assumption.
In summary, we postulate that genetic alterations in
GRIN2B are responsible for 2% (2 of 91) of EE cases,
preferentially causing IS and West syndrome. This fur-
ther strengthens the concept that West syndrome com-
prises a heterogeneous group of several disease entities,
causing increased brain excitability with a similar and
age-related EEG and seizure pattern. Additionally, our
findings reveal further evidence of the contribution of
altered NMDA receptor signaling to epileptogenesis and
establish GRIN2B as another key player in epileptic ence-
phalopathies. In the patients described above, the severity
of phenotypes corresponds to the electrophysiological
severity of gain of ion channel function. This is of partic-
ular interest as existing NMDA receptor blockers such as
memantine represent promising drugs to selectively
restore the altered NMDA receptor function in patients
with gain-of-function mutations in NR2 subunits, put-
ting NMDA receptors more in focus in the search for
new targets in epilepsy treatment.30
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